What does Twist Bioscience do and what are its main business segments?

What is Twist Bioscience's gross profit margin?

What is the market's earnings forecast for Twist Bioscience next quarter?

What were the key takeaways from Twist Bioscience's earnings call?

What is the revenue and EPS growth rate for Twist Bioscience year over year?

What guidance did Twist Bioscience's management provide for the next earnings period?

What factors drove the changes in Twist Bioscience's revenue and profit?

What is Twist Bioscience's latest dividend and current dividend yield?

- **Revenue Growth**: Q1 2026 revenue of $103.7 million (+17% YoY), driven by 27% growth in AI-enabled DNA/Protein Solutions.
- **Margin Expansion**: Gross margin 52.0% (up 400bps YoY), with 74% of incremental revenue flowing to margin.
- **AI Opportunity**: $1.5 billion addressable market for AI-driven discovery, with 50,000+ genes processed in Q1.
- **Profitability Target**: On track for adjusted EBITDA breakeven by Q4 2026.
- **Geographic Growth**: EMEA revenue up 36% YoY, Americas up 9%, APAC up 5%.
- **Therapeutics Expansion**: Therapeutics revenue up 39% YoY, reflecting pharma adoption of AI discovery workflows.

**【CEO Summary Section】**
- Reported Q1 2026 revenue of $103.7 million, up 17% YoY, driven by 27% growth in DNA Synthesis and Protein Solutions (DSPS) and 18% growth in NGS Applications (excluding one large customer). 
- Highlighted 12 consecutive quarters of revenue growth and a 24% CAGR over 3 years, with margin improvement of 20 percentage points.
- Emphasized AI-driven discovery as a $1.5 billion addressable market, with 74% of incremental revenue dropping to gross margin.
- Reaffirmed commitment to achieving adjusted EBITDA breakeven by Q4 2026.

**【COO (Patrick Finn) - AI-Driven Discovery】**
- Detailed three customer segments: large pharma (building models), tech companies (dry lab), and biotech (testing molecules).
- Shared that 50,000+ genes were manufactured for data characterization in Q1, with pricing ranging from $50/fragment to $300-400 for antibody data.
- Highlighted 74% of incremental revenue flowing to gross margin in Q1.

**【CFO (Adam Laponis) Financials】**
- Gross margin improved 400bps YoY to 52.0%, supported by process improvements and scale.
- Operating expenses increased 12% YoY to $86.9 million, driven by commercial and digital investments.
- Adjusted EBITDA loss narrowed to $13.4 million (vs. $16.2 million prior year).
- FY2026 guidance: $435-440 million revenue (16% midpoint growth), Q2 revenue $107-108 million.

**【Q&A Highlights】**
- **AI Demand Durability**: Customers are reordering at scale, with pharma and biotech expanding use cases beyond model building.
- **Gross Margin Strategy**: Maintaining 52%+ gross margin to reinvest in growth, targeting 75-80% incremental margin over time.
- **Partnership Pipeline**: Focused on 2027+ growth through new Diagnostics partnerships, with existing contracts driving 2026 growth.
- **Gene Manufacturing Scale**: 271,000 genes shipped in Q1, up 30% YoY, with 50,000+ genes for data characterization.


Twist Bioscience Corporation (TWST) Q1 2026 Earnings Call Transcript

- **Record Q4 Growth**: $99 million revenue (17% YoY), full-year $376.6 million (20% YoY), with gross margin at 51.3% (up 8 points YoY).
- **AI-Driven Expansion**: SynBio AI discovery orders grew $25 million YoY, Biopharma programs +47% QoQ, targeting 15%-18% 2026 growth.
- **MRD Express Innovation**: Launching 12-hour tumor-informed panels in early 2026, targeting 1-2% NGS growth contribution.
- **Profitability Path**: 2026 gross margin >52%, Q4 2026 adjusted EBITDA breakeven, with $425-$435 million revenue guidance.
- **Market Opportunity**: <10% penetration in key segments, tools business outperforming peers with 75%-80% incremental margin retention.

**【Opening Remarks】**
- Twist Bioscience reported Q4 2025 revenue of $99 million, up 17% YoY, with full-year revenue of $376.6 million (20% YoY growth). Gross margin improved to 51.3% for the quarter and 50.7% annually, up 8 percentage points from 2024.

**【CEO Commentary】**
- **SynBio Growth**: SynBio revenue reached $39.5 million (17% YoY), driven by AI-driven drug discovery projects, which grew by $25 million YoY. Orders from AI customers hit a record $11.5 million in Q4.
- **NGS Expansion**: NGS revenue was $53 million (16% YoY), with 35% YoY growth in EMEA. The company introduced FlexPrep for population genetics and AgBio, securing two major population genetics wins.
- **Biopharma Integration**: Biopharma revenue rose 22% YoY to $6.4 million, with 84 active programs, reflecting convergence with SynBio for end-to-end therapeutics discovery.
- **New Segment Reporting**: SynBio and Biopharma will be combined into "DNA Synthesis and Protein Solutions," while NGS will be rebranded as "NGS Applications" to better reflect customer workflows.

**【CFO Financial Commentary】**
- **2026 Guidance**: Total revenue expected $425-$435 million (13%-15.5% YoY growth). DNA Synthesis & Protein Solutions: $194-$199 million (15%-18% YoY). NGS Applications: $231-$236 million (11%-13.5% YoY). Gross margin >52% for the year, with Q4 2026 targeting adjusted EBITDA breakeven.
- **Key Drivers**: AI discovery orders, MRD Express launch (12-hour panel turnaround), and a large diagnostic customer ramp starting Q2 2026.
- **Cash Flow**: Ended FY2025 with $232.4 million in cash, down $47.6 million in operating cash flow due to growth investments.

**【Q&A Highlights】**
- **Gross Margin Sustainability**: CFO Adam Laponis emphasized 75%-80% incremental margin retention, with Q4 2025 showing 80%+ drop-through. COO Paddy Finn highlighted 50%+ gross margin as a new baseline.
- **MRD Express Launch**: President Patrick Finn announced MRD Express for tumor-informed panels in early 2026, targeting 12-hour turnaround to compete with tumor-naive assays.
- **NGS Growth Challenges**: Q1 2026 NGS revenue impacted by a large customer transition, but expected to rebound to 20% YoY growth by Q4 with MRD contributing 1-2% of NGS revenue.
- **Market Penetration**: CEO Emily Leproust noted <10% market penetration in key segments, with tools business outperforming peers despite lower growth rates than diagnostics.


Twist Bioscience Corporation (TWST) Q4 2025 Earnings Call Transcript

- **Revenue Milestone**: Q3 2025 revenue of $96.1 million (+18% YoY) reflects strong execution across SynBio, NGS, and Biopharma.
- **Gross Margin Expansion**: 53.4% gross margin highlights operational efficiency and volume leverage.
- **Product Innovation**: Launch of gene fragments without adapters and AI-driven Biopharma synergies drive new customer acquisition.
- **2025 Guidance**: Narrowed revenue range of $374-376 million and 50.5-51% gross margin underscore disciplined growth.
- **Breakeven Target**: Adjusted EBITDA breakeven expected in 2026, supported by sequential revenue growth and margin discipline.

**【CEO Summary Section】**
- **Record Revenue Growth**: Q3 2025 revenue reached $96.1 million, up 18% YoY, driven by SynBio ($35.2M, +7%), NGS ($55.3M, +27%), and Biopharma ($5.6M, +10%).
- **Gross Margin Expansion**: Gross margin improved to 53.4% (vs. 43.3% Q3 2024), benefiting from volume leverage and product mix.
- **New Product Momentum**: Launch of gene fragments without adapters and Express Genes portfolio expanded customer reach, adding hundreds of net new customers.
- **AI and Biopharma Synergies**: Twist's platform supports AI-driven drug discovery, with growing Biopharma Services orders (+10% YoY).

**【COO Operational Commentary】**
- **SynBio Efficiency**: 75-80% of incremental SynBio revenue drops to gross margin, with 20%+ underlying growth excluding one-time large customer.
- **NGS Strength**: 44% of NGS revenue from top 10 customers, with 155 new NGS adopters in Q3.
- **Global Expansion**: EMEA revenue grew 30% YoY, while APAC remained stable at $5.9 million.
- **Atlas Transaction Impact**: $48.8 million one-time gain from Atlas Data Storage sale, contributing to Q3 net income of $20.4 million.

**【CFO Financial Guidance】**
- **2025 Full Year Outlook**: Narrowed revenue guidance to $374-376 million (+19.7% YoY), with SynBio ($144-145M, +17%), NGS ($207-208M, +23%), and Biopharma ($23M, +13%).
- **Gross Margin Target**: 50.5-51% for FY25, up 8.1 points YoY.
- **Adjusted EBITDA**: Projected loss of $45-47 million, improving by $46 million YoY.
- **Q4 2025 Outlook**: $96-98 million revenue, with NGS expected to face $5 million normalization from a key customer transition.

**【Q&A Highlights】**
- **SynBio Growth Drivers**: New product launches (e.g., gene fragments without adapters) and AI-driven demand are key to 20%+ CAGR.
- **NGS Clinical Adoption**: MRD assays expected to ramp in 2026, complementing clinical diagnostic growth.
- **Operational Discipline**: OpEx control and gross margin expansion support adjusted EBITDA breakeven target for 2026.
- **Market Resilience**: U.S. academic revenue grew 10% sequentially, despite funding headwinds, due to platform differentiation.


Twist Bioscience Corporation (TWST) Q3 2025 Earnings Call Transcript

- **Spin-Off Success**: Atlas Data Storage secures $155M funding, positioning Twist for $75M milestones and royalty gains.
- **Revenue Surge**: Q2 2025 revenue up 23% YoY to $92.8M, with NGS and SynBio leading growth.
- **Margin Expansion**: Gross margin jumps to 49.6%, targeting >50% in H2; adjusted EBITDA loss narrows by $11.9M YoY.
- **Customer Engagement**: Promotions drive 20% YoY academic growth; Twist Wallet and Express Gene trials boost retention.
- **Profit Path**: $5M quarterly EBITDA improvement from Atlas; breakeven by end of 2026.

**【CEO Opening Remarks】**
- Announced the spin-off of DNA Data Storage into Atlas Data Storage, a pure-play company with $155M in venture funding. Twist retains 24% equity, $75M in milestone payments, and royalties.
- Q2 revenue reached $92.8M (23% YoY), with gross margin at 49.6% (vs. 41% in Q2 2024). SynBio revenue grew 21% YoY to $36M, NGS to $51.1M (25% YoY), and Biopharma to $5.7M (21% YoY).
- Introduced customer programs like Twist Wallet and Express Gene promotions to drive academic engagement, resulting in 20% YoY academic revenue growth.

**【CFO Financial Highlights】**
- Adjusted EBITDA loss narrowed to $14.8M (vs. $26.7M in Q2 2024), with cash of $257.1M.
- FY25 guidance: $372M-$379M revenue (20% YoY midpoint), gross margin ~49.5%, and breakeven by end of FY26.
- Q3 2025 revenue expected at $94M-$97M (17% YoY midpoint), with sequential improvements in gross margin (>50% in H2).

**【Q&A Key Takeaways】**
- **Tariffs Impact**: Minimal effect on Twist due to U.S.-based supply chain; competitors may face headwinds.
- **Academic Growth**: 20% YoY growth driven by promotions; long-term opportunity to convert makers to buyers.
- **MRD Pipeline**: Customers advancing into clinical studies; potential revenue in 2026.
- **Atlas Spin-Off**: $5M quarterly EBITDA improvement starting Q4; accelerates path to profitability.
- **Pacing**: Back-half revenue weighted (~28% in Q4) reflects sequential growth trends.


Twist Bioscience (TWST)-5 May 25-2025 Q2 Earnings call transcript

- **Revenue Growth Accelerates**: Q1 2025 revenue up 24% YoY to $88.7M, driven by 28% YoY SynBio and 23% YoY NGS growth.
- **Margin Expansion Continues**: Gross margin 48.3% (vs 40.5% Q1 2024), with 81% of incremental revenue dropping to margin line.
- **Express Portfolio Dominance**: 147 new NGS customers adopted products, 89 active Biopharma programs.
- **Tariff Advantage**: Competitors face 16.5% tariffs on Chinese imports, while Twist's US manufacturing avoids costs.
- **2025 Outlook**: $372-379M revenue (20% YoY midpoint), 49% gross margin, $55-60M EBITDA loss.

**【CEO Overview】**
- Q1 2025 revenue reached $88.7 million, up 24% YoY and 5% sequentially, driven by SynBio (28% YoY) and NGS (23% YoY). 
- Gross margin improved to 48.3% (vs 40.5% Q1 2024), with 81% of incremental revenue dropping to the margin line.
- Express portfolio growth: 147 new NGS customers adopted products, 89 active Biopharma programs.
- 2025 guidance raised to $372-379M revenue (20% YoY midpoint), with Q2 targeting $91-93M.

**【CFO Financial Highlights】**
- Adjusted EBITDA loss narrowed to $16.3M (vs $27.8M Q1 2024), with $270.8M cash on hand.
- SynBio gross margin expansion from 44% to 48% due to Express portfolio adoption.
- 2025 gross margin expected to reach 49% (50%+ in Q4), with $55-60M EBITDA loss.

**【Q&A Key Takeaways】**
- Tariffs on Canadian/Mexican imports create headwinds for competitors, benefiting Twist's US-manufactured products.
- Enzyme development pipeline to drive 2025+ margin expansion, with Q4 2025+ gross margin >50%.
- Customer retention rate >90%, with wallet share growth via Express portfolio speed/cost advantage.
- Data storage R&D progressing on enzymatic synthesis for terabyte-scale storage, though capital allocation prioritizes breakeven.


Actual							-0.85	-0.67	-0.54	-0.72	-0.78	-0.82	-0.84	-0.91	-1.13	-1.08	-0.91	-0.74	-1.04	-1.01	-0.81	-0.75	-0.79	-1.47	-0.59	-0.53	-0.66	0.33	-0.45	-0.5
Forecast							-0.755	-0.7025	-0.6929	-0.704	-0.7633	-0.7488	-0.8025	-1.0638	-1.2338	-1.2906	-1.2488	-1.1336	-1.1256	-1.1248	-0.9189	-0.7767	-0.8157	-0.7639	-0.7139	-0.6245	-0.5482	-0.5189	-0.4153	-0.424
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-12.58%	+4.63%	+22.07%	-2.27%	-2.19%	-9.51%	-4.67%	+14.46%	+8.41%	+16.32%	+27.13%	+34.72%	+7.60%	+10.21%	+11.85%	+3.44%	+3.15%	-92.43%	+17.36%	+15.13%	-20.39%	+163.60%	-8.36%	-17.92%

TWST

TWST fundamentals

TWST Q1 2026 Earnings

Earnings Call

You can ask Aime

TWST

TWST fundamentals

TWST Q1 2026 Earnings

Earnings Call

TWST Earnings Call Summary for Q1/20268:00 AM on Feb 2, 2026

TWST Earnings Call Summary for Q4/20258:00 AM on Nov 14, 2025

TWST Earnings Call Summary for Q3/20258:00 AM on Aug 4, 2025

TWST Earnings Call Summary for Q2/20258:00 AM on May 5, 2025

TWST Earnings Call Summary for Q1/20258:00 AM on Feb 3, 2025

You can ask Aime